Biotech Values

[pcrutch]

Quote " Velcade has similar and more than these risks, the difference - read Velcade label - is to identify patients at risk with clearly pre-defined dose reduction strategy"

This is something Onyx presumably has not done, which is another reason why the FDA likely punts the NDA.